Browse News
Filter News
Found 165 articles
-
Cell and Gene Therapy Market Size to Reach USD 97.33 Bn by 2033
4/5/2024
According to the latest research by nova one advisor, the global cell and gene therapy market size was valued at USD 18.13 billion in 2023 and is anticipated to reach around USD 97.33 billion by 2033, growing at a CAGR of 18.3% from 2024 to 2033.
-
NURTEC ODT is Now Available in Canada for the Treatment of Acute Migraine
4/4/2024
NURTEC ODT® (rimegepant) is now available in Canada for use in the acute treatment of migraine, with or without aura in adults older than 18 years of age.
-
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
1/30/2024
Pfizer Inc. (NYSE: PFE) reported financial results for fourth quarter and full-year 2023 and reaffirmed its 2024 financial guidance(5) provided on December 13, 2023.
-
Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resource Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
1/22/2024
Apnimed, Inc. announced Graham Goodrich has joined the company as Chief Commercial Officer and Ted Harding as Chief Human Resources Officer.
-
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
11/13/2023
Teva Pharmaceuticals International GmbH and Royalty Pharma plc (Nasdaq: RPRX), announced today a collaboration to further accelerate the clinical research program for Teva’s olanzapine LAI (TEV-‘749) by entering into a funding agreement of up to $125 million to offset program costs.
-
Pfizer Reports Third-Quarter 2023 Results
10/31/2023
Pfizer Inc. reported financial results for the third quarter of 2023. The company reaffirms its 2023 revenue guidance range of $58.0 to $61.0 billion and its outlook for Adjusted diluted EPS of $1.45 to $1.65 provided on October 13, 2023.
-
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
9/5/2023
Ascendis Pharma A/S and Royalty Pharma plc announced that Ascendis has entered into a $150 million capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net SKYTROFA revenue.
-
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
8/24/2023
Royalty Pharma plc and Ferring Pharmaceuticals announced that Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring’s Adstiladrin® for up to US $500 million comprised of an upfront payment of US $300 million and a US $200 million milestone payment.
-
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
8/14/2023
NewAmsterdam Pharma Company N.V. announced the appointment of William “BJ” Jones as the Company’s first Chief Commercial Officer, effective August 14, 2023.
-
Click Therapeutics Launches Additional Randomized Clinical Study in Migraine, Conducted in Partnership with Syneos Health
8/2/2023
Click Therapeutics, Inc. today announced the launch of its second active randomized clinical trial in migraine, ReMMiD-C, Reduction in Monthly Migraine Days-CGRP study, a fully remote and decentralized trial designed to investigate the efficacy and safety of digital therapeutics in reducing the number of monthly migraine days for adults diagnosed with episodic migraine currently receiving Calcitonin-Gene-Related Peptide (CGRP) inhibitor therapy.
-
In its second-quarter earnings reported Tuesday, Pfizer announced total revenues declined 54% to $12.7 billion, primarily due to a plummet in Paxlovid and Comirnaty sales.
-
Pfizer Reports Second-Quarter 2023 Results
8/1/2023
Pfizer Inc. reported financial results for the second quarter of 2023.
-
Apogee Therapeutics Strengthens Team with Appointments of Industry Leaders to Board of Directors and Management
6/22/2023
Apogee Therapeutics announced the appointments of Jennifer Fox and William “BJ” Jones, seasoned executives in the biotechnology industry, to its board of directors.
-
In the first head-to-head trial of CGRP antagonists, Lilly’s Emgality failed to demonstrate that it was significantly better than Pfizer’s Nurtec ODT at easing migraine headaches.
-
First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention
6/16/2023
Eli Lilly and Company (NYSE: LLY) announced results of the CHALLENGE-MIG clinical trial of Emgality® (galcanezumab-gnlm) and Nurtec® ODT (rimegepant orally disintegrating tablet), the first and only trial of its kind comparing two calcitonin gene-related peptide (CGRP) antagonist therapies.
-
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
5/31/2023
Biohaven Ltd. will provide an overview of clinical progress, regulatory updates, and pipeline developments at an in-person R&D Day , concurrently with the Yale Ventures' Innovation Summit 2023 taking place on May 31-June 1.
-
The company’s pipeline changes come as it weathered a nearly 30% decline in first-quarter revenues due to a slowdown in its COVID-19 business.
-
Pfizer Reports First-Quarter 2023 Results
5/2/2023
Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2023 and reaffirmed full-year 2023 financial guidance.
-
Areteia Therapeutics Announces Appointment of Elyse Stock, M.D. To Board of Directors
4/20/2023
Areteia Therapeutics, Inc. (“Areteia”) today announced the appointment of Elyse Stock, M.D. to the Areteia Board of Directors, effective April 17, 2023.
-
Qulipta’s label expansion makes it the first oral CGRP receptor antagonist approved for episodic and chronic migraine.